DexCom, Inc. (NASDAQ:DXCM) – Piper Jaffray Companies dropped their Q4 2019 earnings estimates for shares of DexCom in a report released on Wednesday, November 6th. Piper Jaffray Companies analyst J. Mckim now expects that the medical device company will post earnings per share of $0.55 for the quarter, down from their prior estimate of $0.62. Piper Jaffray Companies has a “Overweight” rating and a $200.00 price target on the stock. Piper Jaffray Companies also issued estimates for DexCom’s Q1 2020 earnings at $0.11 EPS, Q4 2020 earnings at $0.71 EPS, Q1 2021 earnings at $0.23 EPS and Q2 2021 earnings at $0.40 EPS.
DexCom (NASDAQ:DXCM) last posted its earnings results on Wednesday, November 6th. The medical device company reported $0.65 EPS for the quarter, topping the Zacks’ consensus estimate of $0.20 by $0.45. DexCom had a positive return on equity of 10.41% and a negative net margin of 13.96%. The business had revenue of $396.30 million for the quarter, compared to analysts’ expectations of $348.99 million. During the same quarter in the previous year, the firm earned $0.17 earnings per share. The business’s revenue was up 48.6% compared to the same quarter last year.
A number of other analysts have also recently commented on the company. Guggenheim upgraded DexCom from a “neutral” rating to a “buy” rating in a research report on Thursday. BidaskClub upgraded DexCom from a “hold” rating to a “buy” rating in a research report on Friday, November 1st. Oppenheimer boosted their price target on DexCom from $180.00 to $205.00 in a research report on Thursday. BMO Capital Markets boosted their price target on DexCom from $180.00 to $190.00 and gave the company an “outperform” rating in a research report on Tuesday, September 3rd. Finally, ValuEngine cut DexCom from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Five investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $190.67.
Shares of DXCM traded up $3.38 during midday trading on Friday, reaching $198.08. 2,580,200 shares of the stock were exchanged, compared to its average volume of 1,138,483. The business’s 50-day moving average price is $154.75 and its 200 day moving average price is $145.88. The company has a debt-to-equity ratio of 1.56, a current ratio of 6.05 and a quick ratio of 5.64. DexCom has a twelve month low of $105.05 and a twelve month high of $200.80. The company has a market capitalization of $14.00 billion, a price-to-earnings ratio of 660.27 and a beta of 0.64.
Institutional investors and hedge funds have recently made changes to their positions in the business. Gradient Investments LLC purchased a new stake in DexCom in the 2nd quarter valued at approximately $25,000. Virtus ETF Advisers LLC purchased a new stake in DexCom in the 2nd quarter valued at approximately $29,000. Steward Partners Investment Advisory LLC purchased a new stake in DexCom in the 2nd quarter valued at approximately $31,000. CSat Investment Advisory L.P. purchased a new stake in DexCom in the 2nd quarter valued at approximately $31,000. Finally, Wealthcare Advisory Partners LLC purchased a new stake in DexCom in the 2nd quarter valued at approximately $37,000. 96.19% of the stock is currently owned by institutional investors.
In other DexCom news, EVP Richard Doubleday sold 2,016 shares of DexCom stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $175.14, for a total value of $353,082.24. Following the sale, the executive vice president now owns 72,570 shares of the company’s stock, valued at approximately $12,709,909.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Kevin R. Sayer sold 10,000 shares of DexCom stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $156.12, for a total value of $1,561,200.00. The disclosure for this sale can be found here. Insiders sold a total of 104,014 shares of company stock worth $16,183,576 in the last 90 days. 1.80% of the stock is currently owned by insiders.
DexCom Company Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Recommended Story: Are analyst ratings accurate?
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.